Combined Metformin and Clomiphene Citrate Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome
20 Years
36 Years
Female
Polycystic Ovary Syndrome
Trial Information
Combined Metformin and Clomiphene Citrate Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome
All patients in the combined metformin-CC group received metformin HCl (Cidophage®;Chemical
Industries Development,Cairo, Egypt), 500 mg thrice daily for 6-8 weeks. Then after the end
of this period, they received 100 mg CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt)
for 5 days starting from day 3 of menstruation (increased by 50 mg in the next cycle in case
of anovulation ). Patients continued treatment for up to six cycles. Metformin was stopped
only when pregnancy was documented. All patients in the control group underwent laparoscopic
ovarian diathermy, then followed up for 6 months.
Inclusion Criteria:
- CC resistant PCOS
Exclusion Criteria:
- Congenital adrenal hyperplasia
- Cushing syndrome
- Androgen secreting tumors
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
occurrence of ovulation and midcycle endometrial thickness (mm).
Safety Issue:
No
Principal Investigator
Hatem Abu Hashim, MD. MRCOG
Investigator Role:
Principal Investigator
Investigator Affiliation:
Mansoura University Hospitals
Authority:
Egypt: Institutional Review Board
Study ID:
MU- 012
NCT ID:
NCT00969631
Start Date:
September 2005
Completion Date:
February 2009
Related Keywords:
- Polycystic Ovary Syndrome
- Polycystic ovary syndrome
- clomiphene resistance
- metformin
- laparoscopic ovarian diathermy
- Polycystic Ovary Syndrome
Name | Location |
|---|
